Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE

• Published in: Blood Vol. 139; no. 4; pp. 492 - 501
• Main Authors: San-Miguel, Jesus, Avet-Loiseau, Hervé, Paiva, Bruno, Kumar, Shaji, Dimopoulos, Meletios A., Facon, Thierry, Mateos, María-Victoria, Touzeau, Cyrille, Jakubowiak, Andrzej, Usmani, Saad Z., Cook, Gordon, Cavo, Michele, Quach, Hang, Ukropec, Jon, Ramaswami, Priya, Pei, Huiling, Qi, Mia, Sun, Steven, Wang, Jianping, Krevvata, Maria, DeAngelis, Nikki, Heuck, Christoph, Van Rampelbergh, Rian, Kudva, Anupa, Kobos, Rachel, Qi, Ming, Bahlis, Nizar J.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 27.01.2022; American Society of Hematology
• Subjects: Aged; Antibodies, Monoclonal - therapeutic use; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Clinical Trials and Observations; Female; Humans; Male; Middle Aged; Multiple Myeloma - diagnosis; Multiple Myeloma - drug therapy; Neoplasm, Residual - diagnosis; Neoplasm, Residual - drug therapy; Progression-Free Survival; Treatment Outcome

In patients with transplant-ineligible newly diagnosed multiple myeloma (NDMM), daratumumab reduced the risk of disease progression or death by 44% in MAIA (daratumumab/lenalidomide/dexamethasone [D-Rd]) and 58% in ALCYONE (daratumumab/bortezomib/melphalan/prednisone [D-VMP]). Minimal residual disea...